ClinicalTrials.gg

Dyskinesias clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 179 studies for Dyskinesias across more than 10 countries. 24 are recruiting or about to start. 49 of them are mainly about Dyskinesias (how this is decided). Per ClinicalTrials.gov, last updated 2026-10-30. Counting its 16 narrower conditions too, such as Huntington Disease: 1,598 studies, 302 open.

Status

Completed
103
Terminated
27
Recruiting
16
Status unknown
16
Not yet recruiting
6
Withdrawn
3

Phase

Phase 2
56
Phase 3
33
Phase 1
17
Phase 4
7

Where

United States
101
Germany
30
France
28
Canada
23
Spain
22
Italy
17

Who develops what

Add Dyskinesias to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 2 programs from 2 companies, 1 with this as their studies’ main aim; 0 with a live phase 3 study; 1 primary completion in the next 12 months.

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

None given by two companies or more yet.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

The 2 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (1)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • 3 Sept 2027 est.AP-472 · Appello Pharmaceuticals, Inc. · Phase 2 registry mapping onlyNCT07432958 A Study to Evaluate the Effectiveness of Two Doses of AP-472 as Adjunctive Therapy to Levodopa in Parkinson's Disease (PD) Participants With Motor Fluctuations — primary endpoint: Change from Baseline in average daily OFF time on motor diaries for AP-472 compared to placebo (normalized to 16-hour awake time) · 150 enrolled

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Dyskinesias studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here Dopamine agonists 6 · Serotonin receptor agonists 3

Coming up

6studies finish main data collection within a year

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

All 6

Who these studies take

Of the 16 Dyskinesias studies recruiting now, 4 (25%) set no upper age limit and 8 (50%) stop at 75 or younger. 5 (31%) take children under 18. 1 (6%) are for women only and 0 (0%) for men only; 2 (13%) take healthy volunteers.

Recruiting studies that take each age, of 16
AgeWomenMen
105 (31%)5 (31%)
1813 (81%)13 (81%)
3013 (81%)12 (75%)
4013 (81%)12 (75%)
5012 (75%)12 (75%)
6512 (75%)12 (75%)
7512 (75%)12 (75%)
854 (25%)4 (25%)

Across all 179 studies, recruiting or not: 23% stop at 75 or younger and 11% at 65; 19% take children; 1% are for women only and 0% for men only; 13% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

What changed recently

From the registry's own updates since Oct 18, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 179. Browse all 179 → or search them.